385 related articles for article (PubMed ID: 17902052)
21. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
van der Hout AH; van den Ouweland AM; van der Luijt RB; Gille HJ; Bodmer D; Brüggenwirth H; Mulder IM; van der Vlies P; Elfferich P; Huisman MT; ten Berge AM; Kromosoeto J; Jansen RP; van Zon PH; Vriesman T; Arts N; Lange MB; Oosterwijk JC; Meijers-Heijboer H; Ausems MG; Hoogerbrugge N; Verhoef S; Halley DJ; Vos YJ; Hogervorst F; Ligtenberg M; Hofstra RM
Hum Mutat; 2006 Jul; 27(7):654-66. PubMed ID: 16683254
[TBL] [Abstract][Full Text] [Related]
22. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
23. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
24. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
[TBL] [Abstract][Full Text] [Related]
25. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
[TBL] [Abstract][Full Text] [Related]
26. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
28. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J
Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878
[TBL] [Abstract][Full Text] [Related]
29. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Smith SA; Richards WE; Caito K; Hanjani P; Markman M; DeGeest K; Gallion HH
Gynecol Oncol; 2001 Dec; 83(3):586-92. PubMed ID: 11733976
[TBL] [Abstract][Full Text] [Related]
31. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
Konstantopoulou I; Kroupis C; Ladopoulou A; Pantazidis A; Boumba D; Lianidou ES; Petersen MB; Florentin L; Chiotellis E; Nounesis G; Efstathiou E; Skarlos D; Tsionou C; Fountzilas G; Yannoukakos D
Hum Mutat; 2000 Sep; 16(3):272-3. PubMed ID: 10980541
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
Ruiz-Flores P; Sinilnikova OM; Badzioch M; Calderon-Garcidueñas AL; Chopin S; Fabrice O; González-Guerrero JF; Szabo C; Lenoir G; Goldgar DE; Barrera-Saldaña HA
Hum Mutat; 2002 Dec; 20(6):474-5. PubMed ID: 12442275
[TBL] [Abstract][Full Text] [Related]
34. A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
Wárlám-Rodenhuis CC; Koot VC; van der Luijt RB; Vasen HF; Ausems MG
Eur J Cancer; 2005 Jul; 41(10):1409-15. PubMed ID: 15955690
[TBL] [Abstract][Full Text] [Related]
35. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Majdak EJ; De Bock GH; Brozek I; Perkowska M; Ochman K; Debniak J; Milczek T; Cornelisse CJ; Jassem J; Emerich J; Limon J; Devilee P
Eur J Cancer; 2005 Jan; 41(1):143-50. PubMed ID: 15617999
[TBL] [Abstract][Full Text] [Related]
37. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
38. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Woodward AM; Davis TA; Silva AG; Kirk JA; Leary JA;
J Med Genet; 2005 May; 42(5):e31. PubMed ID: 15863663
[TBL] [Abstract][Full Text] [Related]
39. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.
Górski B; Debniak T; Jakubowska A; Cybulski C; Huzarski T; Byrski T; Złowocka E; Lubiński J
J Appl Genet; 2003; 44(3):419-23. PubMed ID: 12923317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
